Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10954336-B2
Publication Date
2021-03-23
Expiration Date
Abstract
A cyclic poly L-lactic acid composition having a pH of 6 to 7 by the polymer itself.
Core Innovation
The invention relates to a cyclic poly L-lactic acid composition having a pH of 6 to 7 by the polymer itself. The cyclic poly L-lactic acid has a cyclic polymerization degree (n) of 5 to 30, and a cyclic polymerization degree (n) of 5 to 10 shows an ionic strength of 50% or more.
The document contrasts the disclosed cyclic poly L-lactic acid compositions with conventional lower-ionic-strength cyclic oligomers that remain acidic and require additives. Conventional oligomers with ionic strength of 4% or less and a cyclic polymerization degree (n) in a higher range are described as remaining acidic and requiring neutralizers and/or sweeteners.
The described compositions are characterized by analytical comparisons of cyclic versus chain/linear fractions using MALDI/MS and high-resolution ESI/MS. The document also supports production of acidity-free cyclic poly L-lactic acid and discusses controlled dehydration condensation with repeated pressure raising and lowering in a specified temperature range to generate high-purity cyclic material [procedural detail omitted for safety].
Claims Coverage
The document includes independent claim coverage for a self-buffered cyclic poly L-lactic acid composition defined by pH 6 to 7 by the polymer itself, a cyclic polymerization degree (n) of 5 to 30, and an ionic strength threshold for the n=5 to 10 subset, with related dependent coverage for optional chain poly L-lactic acid content and pharmaceutical products including the disclosed compositions.
Self-buffered cyclic poly L-lactic acid composition with pH 6 to 7 by the polymer itself
A cyclic poly L-lactic acid composition having a pH of 6 to 7 by the polymer itself, wherein the cyclic poly L-lactic acid has a cyclic polymerization degree (n) of 5 to 30.
High-ionic-strength n=5 to 10 cyclic poly L-lactic acid subset
The cyclic poly L-lactic acid having the cyclic polymerization degree (n) of 5 to 10 shows an ionic strength of 50% or more.
Optional chain poly L-lactic acid component
The composition additionally includes a chain poly L-lactic acid with a chain polymerization degree (n) of 2 to 30.
Pharmaceutical product compounded with the cyclic poly L-lactic acid composition
A pharmaceutical product in which the cyclic poly L-lactic acid composition is compounded.
Pharmaceutical product including a compound formed with cyclic poly L-lactic acid composition plus chain component
A pharmaceutical product that includes a compound formed from the cyclic poly L-lactic acid composition, where the compound corresponds to the version including the additional chain poly L-lactic acid component.
Overall, the claim set focuses on self-buffering cyclic poly L-lactic acid at pH 6 to 7 by the polymer itself, with cyclic polymerization degree (n) constrained to 5 to 30 and a high-ionic-strength requirement for the n=5 to 10 subset, optionally combined with chain poly L-lactic acid and further narrowed to pharmaceutical products compounded from the disclosed compositions.
Stated Advantages
Provides a cyclic poly L-lactic acid composition that achieves a pH of 6 to 7 by the polymer itself.
Avoids the need for added neutralizers/sweeteners as described in the contrast with conventional acidic cyclic oligomers that require additives.
Produces acidity-free cyclic poly L-lactic acid with high purity as characterized by MALDI/MS and high-resolution ESI/MS.
Documented Applications
Pharmaceutical products are described as containing the disclosed cyclic poly L-lactic acid compositions.
Proposed medical uses include acting as a metabolic regulator/inhibitor, immune activation, LDH inhibition, and a cancer therapeutic agent.
Human case examples are described in connection with cancers including gastric cancer/lung metastasis, skin cancer, cervical cancer, colorectal cancer, prostate cancer, and other cited cases [procedural detail omitted for safety].
Interested in licensing this patent?